Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 4 (2007), Issue 1 (January)

1. Treatment and outcomes of malignant melanoma of the eyelid: a review of 29 cases in Australia.
   Ophthalmology, 114(1): 187-92. [Abstract] [Full-text]
2. Fluorescent in situ hybridization for monosomy 3 via 30-gauge fine-needle aspiration biopsy of choroidal melanoma in vivo.
   Ophthalmology, 114(1): 142-6. [Abstract] [Full-text]
3. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma.
   J Thorac Cardiovasc Surg, 133(1): 104-10. [Abstract] [Full-text]
4. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
   Cancer, 109(1): 100-8. [Abstract] [Full-text]
5. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry.
   Genes Chromosomes Cancer, 46(3): 277-87. [Abstract] [Full-text]
6. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.
   Proc Natl Acad Sci U S A, 104(1): 252-7. [Abstract] [Full-text]
7. Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo.
   Biochem Biophys Res Commun, 353(2): 418-23. [Abstract] [Full-text]
8. Imaging of metastatic melanoma.
   Cancer Imaging, 6: 204-8. [Abstract] [Full-text]
9. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
   Cancer Res, 67(1): 300-8. [Abstract] [Full-text]
10. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
    Cancer Res, 67(1): 209-17. [Abstract] [Full-text]
11. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.
    Cancer Res, 67(1): 122-9. [Abstract] [Full-text]
12. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
    Exp Mol Pathol, 82(1): 68-76. [Abstract] [Full-text]
13. Retrospective review of primary melanomas excised at Waikato Hospital, New Zealand, 2002-2003.
    Australas J Dermatol, 48(1): 14-7. [Abstract] [Full-text]
14. Efficacy of a partner assistance intervention designed to increase skin self-examination performance.
    Arch Dermatol, 143(1): 37-41. [Abstract] [Full-text]
15. Effect of health care delivery models on melanoma thickness and stage in a university-based referral center: an observational pilot study.
    Arch Dermatol, 143(1): 30-6. [Abstract] [Full-text]
16. Visual screening for malignant melanoma: a cost-effectiveness analysis.
    Arch Dermatol, 143(1): 21-8. [Abstract] [Full-text]
17. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma.
    J Invest Dermatol, 127(2): 276-80. [Abstract] [Full-text]
18. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
    J Invest Dermatol, 127(2): 400-10. [Abstract] [Full-text]
19. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
    J Invest Dermatol, 127(2): 387-93. [Abstract] [Full-text]
20. A Web-based data warehouse on gene expression in human malignant melanoma.
    J Invest Dermatol, 127(2): 394-9. [Abstract] [Full-text]
21. Design and synthesis of glycoside inhibitors of glioma and melanoma growth.
    J Med Chem, 50(2): 364-73. [Abstract] [Full-text]
22. Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression.
    Oncogene, 26(3): 339-48. [Abstract] [Full-text]
23. Keyhole limpet hemocyanin potentiates standard immunotherapy for melanoma.
    Am J Surg, 193(2): 284-7. [Abstract] [Full-text]
24. Influence of provider and practice characteristics on melanoma care.
    Am J Surg, 193(2): 206-12. [Abstract] [Full-text]
25. Risk factors for neovascular glaucoma after carbon ion radiotherapy of choroidal melanoma using dose-volume histogram analysis.
    Int J Radiat Oncol Biol Phys, 67(2): 538-43. [Abstract] [Full-text]
26. New insight into BRAF mutations in cancer.
    Curr Opin Genet Dev, 17(1): 31-9. [Abstract] [Full-text]
27. Cutaneous granular cell tumor with epidermal involvement: a potential mimic of melanocytic neoplasia.
    J Cutan Pathol, 34(2): 188-94. [Abstract] [Full-text]
28. Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review.
    J Cutan Pathol, 34(2): 139-45. [Abstract] [Full-text]
29. Epigenetic inactivation of RASSF1a in uveal melanoma.
    Invest Ophthalmol Vis Sci, 48(2): 486-90. [Abstract] [Full-text]
30. Chemotherapy for metastatic melanoma: time for a change?
    Cancer, 109(3): 455-64. [Abstract] [Full-text]
31. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review.
    Int J Cancer, 120(5): 1116-22. [Abstract] [Full-text]
32. Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: Clinicopathologic analysis of 29 cases.
    Am J Surg Pathol, 31(2): 185-92. [Abstract] [Full-text]
33. In vivo spin trapping of nitric oxide from animal tumors.
    Nitric Oxide, 16(2): 202-8. [Abstract] [Full-text]
34. Allyl isothiocyanate (AITC) and phenyl isothiocyanate (PITC) inhibit tumour-specific angiogenesis by downregulating nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) production.
    Nitric Oxide, 16(2): 247-57. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.